ReviewCell biochemistry and function2026
Posttranslational Modification Cross-Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis.
Review in Cell biochemistry and function, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is driven by coordinated changes in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs). Post-translational modifications (PTMs), phosphorylation, acetylation, ubiquitination, SUMOylation, O-GlcNAcylation, palmitoylation, ISGylation, and ADP-ribosylation, integrate metabolic, inflammatory, and mechanical inputs at a limited number of signaling nodes. This review argues that these modifications interact according to four definable relationships rather than merely co-occurring. In competitive cross-talk, two marks contest one acceptor residue, as when O-GlcNAcylation displaces phosphorylation at the Akt site of endothelial nitric oxide synthase. In hierarchical cross-talk, one modification licenses another, as when Ser536 phosphorylation of NF-κB p65 recruits p300 and permits Lys310 acetylation. In enzyme-directed cross-talk, a modification acts on the writer or eraser of a different system, as HDAC9 does on IκB kinases. In cofactor-coupled cross-talk, sirtuin-dependent deacylation and PARP1-dependent ADP-ribosylation draw on one limiting NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.